# GRM2

## Overview
The GRM2 gene encodes the glutamate metabotropic receptor 2 (mGluR2), a G-protein-coupled receptor (GPCR) that plays a pivotal role in the central nervous system by modulating neurotransmission. As a member of the metabotropic glutamate receptor family, mGluR2 is characterized by its seven-transmembrane domain structure, which is typical of GPCRs, and its ability to form homodimers for functional activity (Enz2012Structure; Kew2005Ionotropic). The receptor is primarily involved in inhibiting adenylyl cyclase activity through coupling with Gi/o proteins, leading to decreased cyclic AMP levels and modulation of synaptic transmission (Pin1995The; Conn1997PHARMACOLOGY). mGluR2 is expressed in various brain regions, including the prefrontal cortex and hippocampus, where it regulates neurotransmitter release and synaptic plasticity, thus influencing cognitive functions and mood (Muguruza2016Group; Mao2022Phosphorylation). Due to its significant role in maintaining synaptic homeostasis, mGluR2 is a potential target for therapeutic interventions in neuropsychiatric disorders (Bocchio2019Group).

## Structure
The GRM2 gene encodes the metabotropic glutamate receptor 2 (mGluR2), a G-protein-coupled receptor involved in neurotransmission. The primary structure of mGluR2 consists of a sequence of amino acids that form a seven-transmembrane domain typical of GPCRs (Kew2005Ionotropic). The secondary structure includes alpha-helices and beta-sheets, contributing to the receptor's stability and function (Feng2015Allosteric). 

The tertiary structure of mGluR2 features a large bi-lobed extracellular N-terminal domain, known as the Venus Flytrap domain, which contains the glutamate binding site. This domain is linked to the transmembrane heptahelical domain, characteristic of GPCRs (Kew2005Ionotropic). The receptor's C-terminus is intracellular and interacts with proteins such as calmodulin, playing a role in signal transduction (Enz2012Structure).

In terms of quaternary structure, functional mGluR2 receptors are homodimers stabilized by disulfide bonds and hydrophobic interactions (Kew2005Ionotropic). Common post-translational modifications of mGluR2 include phosphorylation and glycosylation, which are crucial for its regulatory functions (Enz2012Structure). These structural features enable mGluR2 to modulate synaptic transmission and neuronal excitability effectively.

## Function
The GRM2 gene encodes the metabotropic glutamate receptor 2 (mGluR2), which is a G-protein-coupled receptor involved in modulating neurotransmission in the central nervous system. mGluR2 is primarily coupled to Gi/o proteins, leading to the inhibition of adenylyl cyclase activity and a subsequent decrease in cyclic AMP (cAMP) levels (Pin1995The; Conn1997PHARMACOLOGY). This receptor is predominantly located at presynaptic terminals, where it functions as an autoreceptor to suppress excessive glutamate release, thereby maintaining synaptic homeostasis (Muguruza2016Group; Mao2022Phosphorylation).

mGluR2 is highly expressed in several brain regions, including the prefrontal cortex, striatum, thalamus, hippocampus, and amygdala, which are associated with emotion, learning, memory, and behavior (Muguruza2016Group; Mao2022Phosphorylation). The receptor also modulates the release of other neurotransmitters, such as GABA, dopamine, norepinephrine, and serotonin, contributing to its role in regulating synaptic plasticity and neuronal excitability (Muguruza2016Group; Mao2022Phosphorylation). Through these mechanisms, mGluR2 plays a critical role in cognitive functions and mood regulation, making it a potential target for therapeutic interventions in neuropsychiatric disorders (Bocchio2019Group).

## Clinical Significance
Mutations and alterations in the GRM2 gene have been implicated in several psychiatric disorders. Research has shown a significant association between GRM2 and methamphetamine-induced psychosis in a Japanese population, suggesting that changes in this gene may contribute to the pathophysiology of this condition (Tsunoka2010Association). However, no association was found between GRM2 and schizophrenia in the same population, indicating that its role may be specific to methamphetamine-induced psychosis rather than schizophrenia (Tsunoka2010Association).

In studies involving rats, GRM2 expression levels in the prefrontal cortex have been linked to sensorimotor gating deficiencies, which are often observed in neurodevelopmental disorders like schizophrenia. This suggests that GRM2 may play a role in the regulation of sensorimotor gating, potentially affecting conditions characterized by such disruptions (Østerbøg2019Metabotropic).

Epigenetic changes, such as promoter hypermethylation of GRM2, have been associated with schizophrenia, with increased expression levels observed in patients compared to healthy controls. This indicates that epigenetic modulation of GRM2 may influence the risk of developing schizophrenia (KordiTamandani2013Evaluation). These findings highlight the potential clinical significance of GRM2 in psychiatric disorders.

## Interactions
GRM2, or glutamate metabotropic receptor 2, is involved in various protein-protein interactions that influence its function and signaling pathways. GRM2 can heterodimerize with the 5-HT2A serotonin receptor through their transmembrane domains, specifically domains 4 and 5, forming a dimerization interface. This interaction is mediated by hydrogen bonds and hydrophobic microdomains, and is linked to psychosis, making it a potential target for schizophrenia treatment (Enz2012Metabotropic).

GRM2 also interacts with scaffold proteins such as Tamalin, which binds to its C-terminal domain. This interaction is crucial for the expression and targeting of GRM2 and other group I and II receptors (Enz2006The). Protein kinases like PKA phosphorylate GRM2, suggesting a conserved phosphorylation mechanism that regulates its activity (Enz2006The).

Additionally, GRM2 is part of macromolecular signaling complexes that include various proteins such as kinases, phosphatases, and cytoskeleton-associated proteins. These complexes regulate synaptic function and are involved in signal transduction pathways (Qian2016Metabotropic). The interactions of GRM2 with these proteins are significant for its role in modulating neurotransmission and synaptic plasticity.


## References


[1. (Enz2006The) Ralf Enz. The trick of the tail: protein–protein interactions of metabotropic glutamate receptors. BioEssays, 29(1):60–73, December 2006. URL: http://dx.doi.org/10.1002/bies.20518, doi:10.1002/bies.20518. This article has 63 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bies.20518)

[2. (Pin1995The) J.-P. Pin and R. Duvoisin. The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 34(1):1–26, January 1995. URL: http://dx.doi.org/10.1016/0028-3908(94)00129-g, doi:10.1016/0028-3908(94)00129-g. This article has 1780 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/0028-3908(94)00129-g)

[3. (Bocchio2019Group) Marco Bocchio, Istvan P. Lukacs, Richard Stacey, Puneet Plaha, Vasileios Apostolopoulos, Laurent Livermore, Arjune Sen, Olaf Ansorge, Martin J. Gillies, Peter Somogyi, and Marco Capogna. Group ii metabotropic glutamate receptors mediate presynaptic inhibition of excitatory transmission in pyramidal neurons of the human cerebral cortex. Frontiers in Cellular Neuroscience, January 2019. URL: http://dx.doi.org/10.3389/fncel.2018.00508, doi:10.3389/fncel.2018.00508. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2018.00508)

[4. (Tsunoka2010Association) Tomoko Tsunoka, Taro Kishi, Tsuyoshi Kitajima, Tomo Okochi, Takenori Okumura, Yoshio Yamanouchi, Yoko Kinoshita, Kunihiro Kawashima, Hiroshi Naitoh, Toshiya Inada, Hiroshi Ujike, Mitsuhiko Yamada, Naohisa Uchimura, Ichiro Sora, Masaomi Iyo, Norio Ozaki, and Nakao Iwata. Association analysis of grm2 and htr2a with methamphetamine-induced psychosis and schizophrenia in the japanese population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(4):639–644, May 2010. URL: http://dx.doi.org/10.1016/j.pnpbp.2010.03.002, doi:10.1016/j.pnpbp.2010.03.002. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.pnpbp.2010.03.002)

[5. (Enz2012Metabotropic) Ralf Enz. Metabotropic glutamate receptors and interacting proteins: evolving drug targets. Current Drug Targets, 13(1):145–156, January 2012. URL: http://dx.doi.org/10.2174/138945012798868452, doi:10.2174/138945012798868452. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/138945012798868452)

[6. (KordiTamandani2013Evaluation) Dor Mohammad Kordi-Tamandani, Nahid Dahmardeh, and Adam Torkamanzehi. Evaluation of hypermethylation and expression pattern of gmr2, gmr5, gmr8, and gria3 in patients with schizophrenia. Gene, 515(1):163–166, February 2013. URL: http://dx.doi.org/10.1016/j.gene.2012.10.075, doi:10.1016/j.gene.2012.10.075. This article has 43 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2012.10.075)

[7. (Mao2022Phosphorylation) Li-Min Mao, Nirav Mathur, Tayyibah Mahmood, Sri Rajan, Xiang-Ping Chu, and John Q. Wang. Phosphorylation and regulation of group ii metabotropic glutamate receptors (mglu2/3) in neurons. Frontiers in Cell and Developmental Biology, November 2022. URL: http://dx.doi.org/10.3389/fcell.2022.1022544, doi:10.3389/fcell.2022.1022544. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2022.1022544)

[8. (Feng2015Allosteric) Zhiwei Feng, Shifan Ma, Guanxing Hu, and Xiang-Qun Xie. Allosteric binding site and activation mechanism of class c g-protein coupled receptors: metabotropic glutamate receptor family. The AAPS Journal, 17(3):737–753, March 2015. URL: http://dx.doi.org/10.1208/s12248-015-9742-8, doi:10.1208/s12248-015-9742-8. This article has 30 citations.](https://doi.org/10.1208/s12248-015-9742-8)

[9. (Enz2012Structure) Ralf Enz. Structure of metabotropic glutamate receptor c-terminal domains in contact with interacting proteins. Frontiers in Molecular Neuroscience, 2012. URL: http://dx.doi.org/10.3389/fnmol.2012.00052, doi:10.3389/fnmol.2012.00052. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2012.00052)

[10. (Qian2016Metabotropic) Feng Qian and Feng-Ru Tang. Metabotropic glutamate receptors and interacting proteins in epileptogenesis. Current Neuropharmacology, 14(5):551–562, June 2016. URL: http://dx.doi.org/10.2174/1570159x14666160331142228, doi:10.2174/1570159x14666160331142228. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.2174/1570159x14666160331142228)

[11. (Østerbøg2019Metabotropic) Tina Becher Østerbøg, Doan Minh On, Ignasi Oliveras, Cristóbal Río-Álamos, Ana Sanchez-Gonzalez, Carles Tapias-Espinosa, Adolf Tobeña, Javier González-Maeso, Alberto Fernández-Teruel, and Susana Aznar. Metabotropic glutamate receptor 2 and dopamine receptor 2 gene expression predict sensorimotor gating response in the genetically heterogeneous nih-hs rat strain. Molecular Neurobiology, 57(3):1516–1528, November 2019. URL: http://dx.doi.org/10.1007/s12035-019-01829-w, doi:10.1007/s12035-019-01829-w. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12035-019-01829-w)

[12. (Muguruza2016Group) Carolina Muguruza, J. Javier Meana, and Luis F. Callado. Group ii metabotropic glutamate receptors as targets for novel antipsychotic drugs. Frontiers in Pharmacology, May 2016. URL: http://dx.doi.org/10.3389/fphar.2016.00130, doi:10.3389/fphar.2016.00130. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2016.00130)

[13. (Conn1997PHARMACOLOGY) P. Jeffrey Conn and Jean-Philippe Pin. Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology, 37(1):205–237, April 1997. URL: http://dx.doi.org/10.1146/annurev.pharmtox.37.1.205, doi:10.1146/annurev.pharmtox.37.1.205. This article has 2434 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1146/annurev.pharmtox.37.1.205)

[14. (Kew2005Ionotropic) James N. C. Kew and John A. Kemp. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology, 179(1):4–29, February 2005. URL: http://dx.doi.org/10.1007/s00213-005-2200-z, doi:10.1007/s00213-005-2200-z. This article has 548 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00213-005-2200-z)